JP2006518182A - Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット - Google Patents

Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット Download PDF

Info

Publication number
JP2006518182A
JP2006518182A JP2004502932A JP2004502932A JP2006518182A JP 2006518182 A JP2006518182 A JP 2006518182A JP 2004502932 A JP2004502932 A JP 2004502932A JP 2004502932 A JP2004502932 A JP 2004502932A JP 2006518182 A JP2006518182 A JP 2006518182A
Authority
JP
Japan
Prior art keywords
nucleic acid
prostate cancer
sequence
diagnostic marker
cancer antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2004502932A
Other languages
English (en)
Japanese (ja)
Inventor
スターンズ，マーク
フー，ユージ
ワング，ミン
Original Assignee
フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン filed Critical フイラデルフイア・ヘルス・アンド・エデユケーシヨン・コーポレーシヨン
Publication of JP2006518182A publication Critical patent/JP2006518182A/ja
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57555—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2004502932A 2002-05-07 2003-05-07 Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット Withdrawn JP2006518182A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/140,602 US7790861B2 (en) 1999-09-24 2002-05-07 Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
PCT/US2003/014098 WO2003094844A2 (en) 2002-05-07 2003-05-07 Prostate cancer-related compositions, methods, and kits based on dna macroarray proteomics platforms

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010001962A Division JP2010131022A (ja) 2002-05-07 2010-01-07 Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット

Publications (1)

Publication Number Publication Date
JP2006518182A true JP2006518182A (ja) 2006-08-10

Family

ID=29418388

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2004502932A Withdrawn JP2006518182A (ja) 2002-05-07 2003-05-07 Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット
JP2010001962A Pending JP2010131022A (ja) 2002-05-07 2010-01-07 Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010001962A Pending JP2010131022A (ja) 2002-05-07 2010-01-07 Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット

Country Status (8)

Country Link
US (1) US7790861B2 (https=)
EP (1) EP1507787B1 (https=)
JP (2) JP2006518182A (https=)
AT (1) ATE534654T1 (https=)
AU (1) AU2003239357B2 (https=)
CA (1) CA2484845A1 (https=)
RU (1) RU2004133036A (https=)
WO (1) WO2003094844A2 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101310185A (zh) * 2005-09-19 2008-11-19 约翰·霍普金斯大学 前列腺癌的生物标记
JP2007222160A (ja) * 2006-01-26 2007-09-06 National Institute Of Advanced Industrial & Technology 生体由来試料中の蛋白質の解析方法
KR101666228B1 (ko) 2007-09-28 2016-10-13 인트렉손 코포레이션 생물치료학적 분자를 발현시키기 위한 치료학적 유전자-스위치 작제물 및 생물반응기, 및 이의 용도
CN101469348B (zh) * 2008-08-29 2011-07-20 苏州福英基因科技有限公司 一种前列腺癌症早期的原位杂交检测试剂盒及其检测方法和应用
JP6941565B2 (ja) * 2015-05-12 2021-09-29 ドレクセル ユニバーシティ がん転移を処置または防止するのに有用な化合物および組成物、ならびにこれらの使用法
CN108659062B (zh) * 2018-04-18 2021-06-22 中国农业科学院兰州畜牧与兽药研究所 唾液酸寡糖-磁纳米酶及其制备方法和应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021828A1 (en) * 1999-09-24 2001-03-29 Philadelphia, Health And Education Corporation A pcam-1 marker protein, nucleic acid sequences encoding pcam-1 and immunoassays for detection of pcam-1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5763209A (en) 1988-09-26 1998-06-09 Arch Development Corporation Methods and materials relating to the functional domains of DNA binding proteins
US5578444A (en) 1991-06-27 1996-11-26 Genelabs Technologies, Inc. Sequence-directed DNA-binding molecules compositions and methods
US6066452A (en) 1997-08-06 2000-05-23 Yale University Multiplex selection technique for identifying protein-binding sites and DNA-binding proteins
US20020042062A1 (en) * 1999-09-24 2002-04-11 Mark Stearns Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
CA2399776A1 (en) * 2000-02-03 2001-08-09 Hyseq, Inc. Novel nucleic acids and polypeptides
US6812339B1 (en) * 2000-09-08 2004-11-02 Applera Corporation Polymorphisms in known genes associated with human disease, methods of detection and uses thereof
JP2008500009A (ja) * 2003-03-03 2008-01-10 ジェネンテック・インコーポレーテッド 全身性エリテマトーデスの治療のための組成物と方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001021828A1 (en) * 1999-09-24 2001-03-29 Philadelphia, Health And Education Corporation A pcam-1 marker protein, nucleic acid sequences encoding pcam-1 and immunoassays for detection of pcam-1

Also Published As

Publication number Publication date
EP1507787B1 (en) 2011-11-23
US7790861B2 (en) 2010-09-07
JP2010131022A (ja) 2010-06-17
WO2003094844A3 (en) 2004-09-10
AU2003239357B2 (en) 2010-05-20
US20030100033A1 (en) 2003-05-29
ATE534654T1 (de) 2011-12-15
WO2003094844A2 (en) 2003-11-20
EP1507787A2 (en) 2005-02-23
EP1507787A4 (en) 2006-04-19
CA2484845A1 (en) 2003-11-20
AU2003239357A1 (en) 2003-11-11
RU2004133036A (ru) 2005-06-27

Similar Documents

Publication Publication Date Title
DK2081586T3 (en) RSPONDINES AS MODULATORS OF ANGIOGENESE AND VASCULOGENESES
JP4458551B2 (ja) 哺乳類アポトーシス抑制性蛋白質遺伝子ファミリー、プライマー、プローブおよび検出法
JP5603145B2 (ja) 疾患のイメージング、診断、及び治療
US8206899B2 (en) Prostate cancer-related compositions, methods and kits based on DNA microarray proteomics platforms
JP2002509734A (ja) 腫瘍形成におけるｃｘｃｒ−４遺伝子の役割に基く治療的および診断的応用
KR20020073181A (ko) Ｌｉｖ-1 관련 단백질, 이를 코딩하는 폴리뉴클레오티드및 암의 치료를 위한 그의 용도
JP2010131022A (ja) Ｄｎａマクロアレイプロテオミクスプラットフォームに基づく前立腺癌関連組成物、方法およびキット
JP2010051330A (ja) Ｔｓ１０ｑ２３．３と称する腫瘍抑制因子
JP4005135B2 (ja) 神経アポトーシス抑制性蛋白質（ｎａｉｐ）の使用
JP2009536526A (ja) Ｚｐａポリペプチドに関連する方法および組成物
JPH1175873A (ja) 新規化合物
US20050059120A1 (en) Compositions, methods, and kits relating to resistin-like molecules
JP2003508011A (ja) ヒトｆｅｚ１遺伝子である新規ガン抑制遺伝子に関する組成物、キットおよび方法
CN102134275B (zh) 表皮生长因子受体变异体
JP2006521810A (ja) 免疫関連疾患の治療のための新規組成物と方法
US6630325B1 (en) Compositions, methods and kits relating to remodel
JP2004520814A (ja) 肺特異的遺伝子に関する組成物および方法
US7754435B2 (en) Prostate cancer-related compositions, methods, and kits based on DNA macroarray proteomics platforms
KR20010085816A (ko) 면역 관련 질환 치료용 조성물 및 치료 방법
JPH10146195A (ja) 良性前立腺肥大と関連するポリヌクレオチドおよびポリペプチド
JP2005507398A (ja) エネルギー恒常性の調節に関与するＢｅｓｔｒｏｐｈｉｎおよびＢｅｓｔｒｏｐｈｉｎ相同性タンパク質
JP2004510408A (ja) 大腸癌の診断、モニタリング、ステージング、イメージングおよび処置の方法
DE60319693T2 (de) Marker fur lungentumoren
JP2005046137A (ja) 新規ヒト遺伝子および遺伝子発現産物
US20030228677A1 (en) AMID protein, nucleic acid molecules, and uses thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060508

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090106

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090707

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091007

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091015

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100107

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101116

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110317